Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone

Overview

Journal J Endocr Soc

Specialty Endocrinology

Date 2019 Aug 13

PMID 31403089

Citations 4

Authors

Husam Ghanim

Sandeep Dhindsa

Kelly Green

Sanaa Abuaysheh

Manav Batra

Antoine Makdissi

Ajay Chaudhuri

Paresh Dandona

Affiliations

Soon will be listed here.

Abstract

Context: One-third of men with type 2 diabetes have subnormal free testosterone concentrations. We evaluated the following: (i) whether bone mineral density (BMD) and bone strength are affected by gonadal status in type 2 diabetes and (ii) the effect of testosterone replacement on markers of osteoblast and osteoclast activity.

Design: This is a econdary analysis of a previously completed, randomized, placebo-controlled trial. Ninety-four men with type 2 diabetes were recruited; 44 had subnormal free testosterone concentrations. Men with subnormal free testosterone concentrations were randomized to receive intramuscular injections of testosterone or placebo every 2 weeks for 22 weeks. Dual energy X-ray absorptiometry scans were performed at baseline and at 23 weeks.

Results: Men with subnormal free testosterone had similar BMD compared with men with normal free testosterone. However, bone strength indices were lower in men with subnormal free testosterone. BMD was related to free estradiol concentrations (r = 0.37, = 0.004 at hip), whereas bone strength was related to free testosterone concentrations (r = 0.41, < 0.001). Testosterone replacement increased osteocalcin concentrations [mean change (95% CI), 3.52 (0.45, 6.59), = 0.008]. C-Terminal telopeptide (CTx) concentrations also increased at 15 weeks but reverted to baseline following that. There were no changes in other bone turnover markers or BMD.

Conclusion: We conclude that testosterone replacement resulted in an increase in osteocalcin and a transient increase in CTx, indicating an increase in osteoblastic activity and transient increase in bone breakdown. Therefore, a major action of testosterone is to increase bone turnover in men with type 2 diabetes.

Citing Articles

PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/β-CATENIN Pathway in Testosterone-Treated Hypogonadal Men.

Bathina S, Prado M, Fuenmayor Lopez V, Colleluori G, Aguirre L, Chen R Biomolecules. 2025; 15(1.

PMID: 39858473 PMC: 11764227. DOI: 10.3390/biom15010079.

Total osteocalcin levels are independently associated with worse testicular function and a higher degree of hypothalamic-pituitary-gonadal axis activation in Klinefelter syndrome.

Carlomagno F, Hasenmajer V, Spaziani M, Tenuta M, Sesti F, Tarantino C J Endocrinol Invest. 2024; 47(12):3049-3056.

PMID: 38773059 PMC: 11549210. DOI: 10.1007/s40618-024-02390-7.

The complex pathophysiology of bone fragility in obesity and type 2 diabetes mellitus: therapeutic targets to promote osteogenesis.

Bathina S, Armamento-Villareal R Front Endocrinol (Lausanne). 2023; 14:1168687.

PMID: 37576965 PMC: 10422976. DOI: 10.3389/fendo.2023.1168687.

Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.

Colleluori G, Aguirre L, Napoli N, Qualls C, Villareal D, Armamento-Villareal R J Clin Endocrinol Metab. 2021; 106(8):e3058-e3068.

PMID: 33735389 PMC: 8599870. DOI: 10.1210/clinem/dgab181.

Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol.

Russo V, Colleluori G, Chen R, Mediwala S, Qualls C, Liebschner M Contemp Clin Trials Commun. 2021; 21:100723.

PMID: 33718653 PMC: 7933702. DOI: 10.1016/j.conctc.2021.100723.

References

Wang C, Swerdloff R, Iranmanesh A, Dobs A, Snyder P, Cunningham G . Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001; 54(6):739-50. DOI: 10.1046/j.1365-2265.2001.01271.x. View

Strotmeyer E, Cauley J, Schwartz A, Nevitt M, Resnick H, Zmuda J . Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res. 2004; 19(7):1084-91. DOI: 10.1359/JBMR.040311. View

Chen P, Satterwhite J, Licata A, Lewiecki E, Sipos A, Misurski D . Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20(6):962-70. DOI: 10.1359/JBMR.050105. View

Lorentzon M, Swanson C, Andersson N, Mellstrom D, Ohlsson C . Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res. 2005; 20(8):1334-41. DOI: 10.1359/JBMR.050404. View

Greenspan S, Coates P, Sereika S, Nelson J, Trump D, Resnick N . Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90(12):6410-7. DOI: 10.1210/jc.2005-0183. View

Louis O, Verlinde S, Thomas M, De Schepper J . Between-centre variability versus variability over time in DXA whole body measurements evaluated using a whole body phantom. Eur J Radiol. 2006; 58(3):431-4. DOI: 10.1016/j.ejrad.2006.01.012. View

Morote J, Orsola A, Abascal J, Planas J, Trilla E, Raventos C . Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2006; 175(5):1679-83. DOI: 10.1016/S0022-5347(05)00999-7. View

Amin S, Zhang Y, Felson D, Sawin C, Hannan M, Wilson P . Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med. 2006; 119(5):426-33. DOI: 10.1016/j.amjmed.2005.10.048. View

Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi G, Dandona P . The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care. 2007; 30(7):1860-1. DOI: 10.2337/dc07-0337. View

10.

Janghorbani M, van Dam R, Willett W, Hu F . Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5):495-505. DOI: 10.1093/aje/kwm106. View

11.

Sanyal A, Hoey K, Modder U, Lamsam J, McCready L, Peterson J . Regulation of bone turnover by sex steroids in men. J Bone Miner Res. 2007; 23(5):705-14. PMC: 2674543. DOI: 10.1359/jbmr.071212. View

12.

Travison T, Araujo A, Beck T, Williams R, Clark R, Leder B . Relation between serum testosterone, serum estradiol, sex hormone-binding globulin, and geometrical measures of adult male proximal femur strength. J Clin Endocrinol Metab. 2008; 94(3):853-60. PMC: 2681275. DOI: 10.1210/jc.2008-0668. View

13.

LeBlanc E, Nielson C, Marshall L, Lapidus J, Barrett-Connor E, Ensrud K . The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009; 94(9):3337-46. PMC: 2741717. DOI: 10.1210/jc.2009-0206. View

14.

Burnett-Bowie S, McKay E, Lee H, Leder B . Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009; 94(12):4785-92. PMC: 2795655. DOI: 10.1210/jc.2009-0739. View

15.

Salameh W, Redor-Goldman M, Clarke N, Reitz R, Caulfield M . Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges. Steroids. 2009; 75(2):169-75. DOI: 10.1016/j.steroids.2009.11.004. View

16.

Ferlin A, Schipilliti M, Di Mambro A, Vinanzi C, Foresta C . Osteoporosis in Klinefelter's syndrome. Mol Hum Reprod. 2010; 16(6):402-10. DOI: 10.1093/molehr/gaq026. View

17.

Modder U, Clowes J, Hoey K, Peterson J, McCready L, Oursler M . Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2010; 26(1):27-34. PMC: 3132405. DOI: 10.1002/jbmr.128. View

18.

Cauley J, Ewing S, Taylor B, Fink H, Ensrud K, Bauer D . Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study. J Clin Endocrinol Metab. 2010; 95(9):4314-23. PMC: 2936055. DOI: 10.1210/jc.2009-2635. View

19.

Clarke B, Khosla S . Female reproductive system and bone. Arch Biochem Biophys. 2010; 503(1):118-28. PMC: 2942975. DOI: 10.1016/j.abb.2010.07.006. View

20.

Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, Dandona P . Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care. 2011; 34(8):1854-9. PMC: 3142021. DOI: 10.2337/dc11-0208. View